Advanced Search

Show simple item record

dc.contributor.authorHasbal, Nuri Baris
dc.contributor.authorKoc, Yener
dc.contributor.authorSakaci, Tamer
dc.contributor.authorSevinc, Mustafa
dc.contributor.authorUcar, Zuhal Atan
dc.contributor.authorSahutoglu, Tuncay
dc.contributor.authorBasturk, Taner
dc.date.accessioned2020-12-02T18:01:27Z
dc.date.available2020-12-02T18:01:27Z
dc.date.issued2020
dc.identifier.issn2667-4440
dc.identifier.urihttps://doi.org/10.5152/turkjnephrol.2020.4130
dc.identifier.urihttp://hdl.handle.net/11446/3624
dc.description34th National Congress of Nephrology -- OCT 18-22, 2017 -- Antalya, TURKEYen_US
dc.descriptionHasbal, Nuri Baris/0000-0002-2229-5140en_US
dc.descriptionWOS: 000547335800006en_US
dc.description.abstractObjective: Atrial fibrillation (AF) is one of the most common and cumulatively important cardiac arrhythmias. Prevalence of AF is much higher in patients with chronic kidney disease (may be up to 27%). We aimed to study the prevalence and clinical features of AF in hemodialysis centers. Materials and Methods: Patients who had been under chronic in-center hemodialysis for at least 6 months and were >= 18 years of age were included in this cross-sectional study conducted at five hemodialysis centers across Istanbul between May 2017 and July 2017. Medical history, clinical (including medications and echocardiography), and laboratory data were obtained using a standardized study form. Results: the data of 632 prevalent patients undergoing in-center hemodialysis (mean age 62.7 +/- 13.9 years, males 350 and females 282) were included in the analysis. AF was present in 92 (14.5%) of the patients. the prevalence of AF was lowest in patients <55 years of age and showed an increasing trend with age. While age, coronary artery disease, heart failure, and cerebrovascular events were associated with the presence of AF; left ventricular hypertrophy, diabetes and hypertension were not. Overall, 78% of patients with AF were using either single or a combination of antithrombotic agents. Less than 10% of AF patients were receiving warfarin. the rates of antiplatelet agents and warfarin use were not different between patients with a CHA2DS2-VASc score of >= 2 or less. Conclusion: AF is highly prevalent in patients undergoing hemodialysis, and warfarin was used in nearly 5% of the patients with AF undergoing hemodialysis in this study, which suggests that the current knowledge is unconvincing to proceed for the treatment with anticoagulation. Further studies are needed to guide the management for prevention of strokes in patients with AF undergoing dialysis.en_US
dc.language.isoengen_US
dc.publisherAvesen_US
dc.relation.isversionof10.5152/turkjnephrol.2020.4130en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnticoagulationen_US
dc.subjectatrial fibrillationen_US
dc.subjecthemodialysisen_US
dc.titlePrevalence and Characteristics of Atrial Fibrillation in Turkish Patients Undergoing Hemodialysisen_US
dc.typeconferenceObjecten_US
dc.relation.journalTurkish Journal of Nephrologyen_US
dc.contributor.departmentDBÜen_US
dc.identifier.issue3en_US
dc.identifier.volume29en_US
dc.identifier.startpage215en_US
dc.identifier.endpage220en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record